New combo attack on tough head & neck cancers
NCT ID NCT07156227
Summary
This early-stage trial is testing whether a new drug called camonsertib, combined with a precise form of radiation therapy, can help control head and neck cancers that have returned or cannot be surgically removed. The main goals are to find the safest dose of the drug-radiation combination and to see what side effects occur. The study will enroll about 39 adults whose cancer has come back in an area previously treated with radiation.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CLINICAL STAGE III HPV-MEDIATED (P16-POSITIVE) OROPHARYNGEAL CARCINOMA AJCC V8 are added.
By submitting, you agree to our Terms of use
Conditions
Explore the condition pages connected to this study.